Companies Dominating the Herpes Simplex Virus Treatment Landscape
- Oncorus, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- SillaJen, Inc.
- Sorrento Therapeutics, Inc.
- Replimune Group Inc.
- Shanghai Sunway Biotech Co., Ltd
- Merck & Co, Inc.
- Amgen Inc.
- Oncolytics Biotech Inc.
- Transgene SA
- PSIOXUS Therapeutics Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of herpes simplex virus treatment is assessed at USD 3.03 billion.
Herpes Simplex Virus Treatment Market size was valued at USD 2.84 billion in 2024 and is expected to reach USD 7.45 billion by 2037, expanding at around 7.7% CAGR during the forecast period i.e., between 2025-2037.
North America industry is predicted to account for largest revenue share by 2037, on the back of high government investment in this sector, along with presence of leading pharmaceutical companies conducting innovative clinical experiments.
The major players in the market are Sorrento Therapeutics, Inc., Replimune Group Inc., Shanghai Sunway Biotech Co., Ltd, Merck & Co, Inc., Amgen Inc., Oncolytics Biotech Inc., Transgene SA, PSIOXUS Therapeutics Limited and others.
